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This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).SUMMARYMonoclonal antibody (mAb) drugs that stimulate antitumor immunity are transforming cancer treatment but
requireoptimization formaximumclinical impact.Here,weshow that,unlikeother immunoglobulin isotypes,hu-
man IgG2 (h2) imparts FcgR-independent agonistic activity to immune-stimulatorymAbs such asanti-CD40, -4-
1BB, and -CD28. Activity is provided by a subfraction of h2, h2B, that is structurally constrained due its
unique arrangement of hinge region disulfide bonds. Agonistic activity can be transferred from h2 to h1 by
swapping their hinge and CH1 domains, and substitution of key hinge and CH1 cysteines generates homoge-
nous h2 variants with distinct agonistic properties. This provides the exciting opportunity to engineer clinical
reagents with defined therapeutic activity regardless of FcgR expression levels in the local microenvironment.INTRODUCTION
Monoclonal antibodies (mAbs) that modulate immune responses
are proving highly effective in cancer treatment, with increasing
evidence that such responses can be harnessed to provide du-
rable eradication of tumors (Hodi et al., 2010; Sliwkowski and
Mellman, 2013; Topalian et al., 2012; Wolchok et al., 2013). Re-
sults with ‘‘checkpoint blocker’’ mAbs designed to antagonize
the inhibitory T cell coreceptors cytotoxic T lymphocyte antigen
4 (CTLA-4) and programmed death 1 have reinforced the view
that T cell immunity can provide long-lasting protection against
aggressive and difficult-to-treat cancers, such as metastatic
melanoma and non-small-cell lung cancer (Hodi et al., 2010;
Topalian et al., 2012; Wolchok et al., 2013). Promising clinical
data are also emerging with immunostimulatory mAbs that
bind agonistically to the costimulatory receptor CD40 on anti-Significance
Monoclonal antibodies (mAbs) that stimulate anticancer imm
traditionally terminal malignancies. Realization of the full poten
provided by a detailed understanding of their mechanisms of a
regions provide mAbs targeting three immunostimulatory core
with agonistic activity independent of Fcg receptor interactio
stream intracellular signaling. This exceptional activity is con
h2 hinge and paves the way for engineering improved clinical r
in the local microenvironment.
138 Cancer Cell 27, 138–148, January 12, 2015 ª2015 The Authorsgen-presenting cells (APCs) (Beatty et al., 2011, 2013; Vonder-
heide and Glennie, 2013) with agents against a number of other
costimulatory targets, such as 4-1BB (CD137), OX40 (CD134),
and glucocorticoid-induced tumor necrosis factor receptor-
related protein (GITR), in clinical development (Moran et al.,
2013). These agonistic agents also have the potential to enhance
therapeutic efficacy of other anticancer mAbs, such as those
directed against CD20 or epidermal growth factor receptor
(EGFR). As demonstrated by Levy and colleagues, stimulation
of 4-1BB on natural killer (NK) cells promotes their cytotoxic
potential and enhances antibody (Ab)-dependent cell-mediated
cytotoxicity (ADCC) of anti-CD20-, anti-EGFR-, or anti-human
epidermal growth factor receptor 2 (HER2)-coated tumor cells
(Kohrt et al., 2011, 2012, 2014). Despite clinical success, how-
ever, only a minority of patients show durable responses to
immunomodulatory agents, and a detailed understanding ofunity provide curative therapy in a subset of patients with
tial of these agents, however, will require precise engineering
ction. Here, we demonstrate that human IgG2 (h2) constant
ceptors in clinical development—CD40, 4-1BB, and CD28—
n that is usually required for receptor clustering and down-
ferred by the unique configuration of disulfide bonds in the
eagents with defined activity regardless of FcgR expression
Cancer Cell
Superagonistic Activity of Human IgG2their mechanisms of action remains unclear, making it difficult to
rationally optimize therapeutic activity.
One factor that has a crucial impact on therapeutic efficacy is
mAb isotype due largely to differences in Fcg receptor (FcgR) in-
teractions that influence events downstream of antigen engage-
ment (Nimmerjahn and Ravetch, 2012; White et al., 2013).
Direct targeting anticancer mAbs, such as anti-CD20, -EGFR,
and -HER2, work at least in part by deletion of their cellular tar-
gets through ADCC and as such require interaction with activa-
tory FcgR on NK cells and macrophages (Clynes et al., 2000;
Kurai et al., 2007; Uchida et al., 2004). Mouse immunoglobulin
G (IgG) 2a and human IgG1 (h1) are effective for this type of agent
as they preferentially engage activatory rather than inhibitory
FcgR (Hamaguchi et al., 2006; Nimmerjahn and Ravetch,
2005). Recent studies in preclinical models have shown a similar
isotype dependence for some immunomodulatory mAbs (anti-
CTLA-4, -GITR, and -OX40) where depletion of target-express-
ing T regulatory cells in the tumor is demonstrated to be at least
partly responsible for therapeutic efficacy (Bulliard et al., 2013,
2014; Simpson et al., 2013). In contrast, mAbs whose effects
rely on agonistic receptor engagement, such as anti-CD40 (Li
and Ravetch, 2011; White et al., 2011, 2014) or apoptosis-pro-
moting anti-death receptor (DR) 4, DR5, and Fas (Li and Ravetch,
2012; Wilson et al., 2011; Xu et al., 2003), appear to rely predom-
inantly on crosslinking by the inhibitory FcgRIIB to deliver their
activity (Li and Ravetch, 2013; White et al., 2011, 2014). For
this type of agent, mouse IgG1 (m1) is optimal in preclinical
models as it binds with sufficient affinity to FcgRIIB to mediate
crosslinking (Li and Ravetch, 2011; White et al., 2011, 2014). A
similar mechanism appears to be required for human mAbs as,
although human IgG isotypes bind with low affinity to FcgRIIB
as determined by surface plasmon resonance (SPR; Bruhns
et al., 2009), enhancing the affinity of human IgG1 to human
FcgRIIB through Fc engineering is effective in bestowing
agonistic activity on non-agonist anti-CD40 mAbs both in vitro
(White et al., 2013) and in mice overexpressing human FcgRIIB
(Li andRavetch, 2011; Li andRavetch, 2012). In addition, Bartho-
lomaeus et al. (2014) show that FcgRIIB-mediated crosslinking is
required to deliver agonist activity to the human IgG4 (h4) anti-
human CD28 mAb, TGN1412, in vitro. This study elegantly con-
firms that at the cell-cell interface, when multiple Fc regions of
immobilized IgG may be engaged by FcgRIIB, the affinity of
human IgG for this receptor binding may be both sufficient and
necessary to promote agonistic activity (Lux et al., 2013). How-
ever, agents that rely on FcgRIIB-mediated crosslinking will
always be limited by the availability of the receptor. An alternative
is to develop superagonistic reagents that promote immune re-
sponses without FcgR engagement (White et al., 2014).
To investigate this latter option, we undertook an evaluation
of the immunomodulatory activity of human IgG isotypes using
mAbs against a number of human costimulatory receptors
(CD40, 4-1BB, and CD28) currently being investigated as thera-
peutic targets. We show that h2 imparts greater immunostimula-
tory activity to these agents than either h1 or h4. Detailed studies
with anti-CD40 demonstrated that this activity did not depend
upon differences in FcgR interaction, but rather on the unique
configuration of disulfide bonds in the h2 hinge and CH1
domains. Furthermore, using genetic engineering, we could
manipulate thesebondsand ‘‘lock’’ themAbs intodifferent config-Curations with contrasting levels of agonistic activity. This strategy
provides the opportunity to develop homogeneous superagonis-
tic therapeutic agents with defined levels of activity that are inde-
pendent of FcgR expression levels in the local microenvironment.
RESULTS
Human IgG Isotypes and Anti-CD40 Activity
To examine the effect of human constant regions on agonistic
activity, we used the anti-human CD40mAbChiLob 7/4 (Chowd-
hury et al., 2014), currently in phase 1 clinical trial in cancer pa-
tients. Agonistic activity was initially assessed by the ability of
ChiLob 7/4 to cause human B cell activation and proliferation
in vitro when chimerized onto different human constant regions.
All chimeras bound similarly to CD40 as determined by flow cy-
tometry (Figure S1A available online). Fab0 fragments of ChiLob
7/4 h1 and ChiLob 7/4 h2 also bound to immobilized hCD40
with similar affinities (10.0 and 10.2 3 109 M, respectively) as
measured by SPR (Figure S1B). When added to purified human
B cells, ChiLob 7/4 h2 caused much greater B cell activation and
proliferation as assessed by homotypic adhesion (cell clumping)
and [3H]thymidine uptake, respectively, compared to ChiLob 7/4
h1 or ChiLob 7/4 h4 (Figure 1A). To determine that Fab0 arm ex-
change did not account for the lack of activity of h4, we intro-
duced a stabilizing S228P mutation into ChiLob 7/4 h4 (Angal
et al., 1993). This alteration (h4* in Figure 1A) did not alter activity.
In preclinical models immune stimulatory and therapeutic
effects of anti-CD40 mAb can be mediated through upregulation
of the costimulatory molecule CD70 on dendritic cells (DCs),
resulting in enhanced CD8 T cell immunity (French et al., 1999,
2007; Sanchez et al., 2007). To compare the ability of ChiLob
7/4 h1 and ChiLob 7/4 h2 to activate human DCs, we assessed
their capacity to upregulate CD70 expression on primary
human Langerhans cells in vitro (Figure 1B), aswell as their ability
to enhance Langerhans cell-induced priming of Epstein-Barr
virus-specific human CD8 T cells measured by interferon g
(IFN-g) production (Figure 1C). Consistent with effects on B cells,
ChiLob 7/4 h2 enhanced both Langerhans cell CD70 expression
and CD8 T cell priming, whereas ChiLob 7/4 h1 did not.
The in vivo agonistic activity of ChiLob 7/4 isotypes was exam-
ined in hCD40 transgenic (Tg) mice (Ahonen et al., 2002). Initial
in vitro studies confirmed that hCD40 in mouse cells responded
to ligation with ChiLob 7/4 similarly to that in human cells, as
ChiLob 7/4 h2 stimulated much greater activation and prolifera-
tion of isolated hCD40 Tg mouse B cells than ChiLob 7/4 h1
(Figure 1D) that was dependent upon the expression of hCD40
(Figure S1C). To test in vivo agonistic activity, we examined the
ability of ChiLob 7/4 to enhance CD8 T cell and Ab responses
when coadministered with the model antigen ovalbumin (OVA).
Consistent with the in vitro data, ChiLob 7/4 h2 stimulated signif-
icantly greater anti-OVA CD8 T cell expansion as well as Ab
responses than observed with ChiLob 7/4 h1 (Figure 1E). Thus,
using a series of both in vitro and in vivo approaches, ChiLob
7/4 demonstrated greater immunostimulatory activity when
expressed with h2 versus h1 or h4 constant regions.
Similar differences between h1 and h2 agonistic activity were
also observed in vivo when we examined the anti-mouse
CD40 mAb 3/23, where again 3/23 h2 but not 3/23 h1 stimulated
potent anti-OVA CD8 T cell and Ab responses (Figure 1F) andancer Cell 27, 138–148, January 12, 2015 ª2015 The Authors 139
Figure 1. Human Isotypes and Anti-CD40 Activity
(A) Activation of human B cells in response to ChiLob 7/4 of the indicated isotypes (1 mg/ml) was assessed after 16 hr by homotypic adhesion (top; bar, 1 mm) and
[3H]thymidine incorporation. Points represent individual samples from two to five experiments per isotype.
(B) Human Langerhans cells were untreated (black line) or incubated (gray line) with ChiLob 7/4 h1, ChiLob 7/4 h2, or isotype control (C) for 18 hr, and CD70
expression was analyzed by flow cytometry; one of two experiments shown.
(C) IFN-g ELISpot assay of BMLF-1-specific CD8+ T cell activation by human leukocyte antigen-matched human Langerhans cells activated with ChiLob 7/4 as in
(B). Data are representative of two experiments in triplicate normalized to activation by unpulsed cells.
(D) Activation of hCD40 Tg B cells by ChiLob 7/4 h1 and ChiLob 7/4 h2 at 200 ng/ml was analyzed as in (A). Points are individual samples from three experiments
performed in duplicate.
(E) hCD40 Tgmicewere immunized with 100 mg of OVAwith or without (Con) 100 mg of the indicated ChiLob 7/4mAb. Circulating endogenousOVA-specific CD8+
T cells were enumerated day 8, and the peak of the response (left) and anti-OVA Ab (right) was determined on day 14. Individual animals from two of four
experiments shown.
(F) Mice (n = 3) adoptively transferred with OTI cells were immunized with 100 mg of endotoxin-free OVA without (Con) or with 100 mg of the indicated 3/23 mAb.
Circulating OTI cells were enumerated at the peak of the response (day 5; left) and anti-OVA Ab at day 14 (right). Combined data from two of more than five
experiments.
(G) C57Bl/6 mice (n = 5) were adoptively transferred with OTI cells, immunized with OVA plus 100 mg of the indicated 3/23 isotypes, and 5 days later were
challenged with EG7 tumor subcutaneously. Survival curves from one of two experiments shown.
(H) BALB/c mice (n = 5) were challenged intravenously (i.v.) with BCL1 tumor cells and 14 days later (when the tumor represented 5%–10% spleen weight
[White et al., 2014]) were given i.v. 100 mg of 3/23 h1, 3/23 h2, or PBS (Con) as indicated. Survival curves from one of two experiments shown. *p < 0.05, **p < 0.01,
***p < 0.001.
See also Figure S1.
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difference in immunostimulatory capacity correlated with differ-
ences in therapeutic activity where 3/23 h2, but not 3/23 h1,
provided protection against tumor development in both a vacci-
nation setting where mice immunized with OVA plus anti-CD40
were challengedwith theOVA-expressing EG7 tumor (Figure 1G)
and a therapeutic setting wheremice with established B cell lym-
phoma (BCL1 lymphoma model [White et al., 2014]; Figure 1H)
were treated with a single 100 mg dose of mAb.
Human IgG2 Activity Is FcgR Independent
The low affinity of h2 for FcgRIIB (Bruhns et al., 2009), the pre-
dominant FcgR on B cells, suggested that, unlike agonistic m1
that uses FcgRIIB as a crosslinker (White et al., 2011), its activity
may be FcgR independent. Indeed, SPR where soluble FcgRs140 Cancer Cell 27, 138–148, January 12, 2015 ª2015 The Authorswere passed over immobilized mAb revealed very little binding
of ChiLob 7/4 h2 to any human or mouse FcgR (Figures S2A
and S2B), whereas ChiLob 7/4 h1 clearly bound hFcgRI, -IIA,
and -IIIA as well as mFcgRI and -IV under the same conditions
(Figures S2A and S2B). Control experiments confirmed the
integrity of the mAb and FcgR proteins used (Figures S2C–
S2E). A number of approaches confirmed the FcgR-independent
activity of h2. First, a pan-blocking anti-FcgRII mAb (AT10) failed
to prevent activation of human B cells by ChiLob 7/4 h2, as as-
sessed by homotypic adhesion and CD23 upregulation (Fig-
ure 2A). In contrast, AT10 completely blocked activation by
ChiLob 7/4 h1 induced in the presence of FcgRII-expressing
crosslinking cells (Figure 2A). Second, removal of the ChiLob
7/4 h2 Fc through pepsin cleavage (producing F(ab0)2 fragments)
did not prevent activation and proliferation of human B cells,
Figure 2. FcgR-Independent Activity of
Human IgG2
(A) Activation of human B cells by ChiLob 7/4 h1 or
ChiLob 7/4 h2 plus or minus a 50-fold excess
of blocking anti-FcgRII (AT10) F(ab0)2 and/or
hFcgRIIB-overexpressing 293F cells (+/ FcgRII)
as indicated, assessed by homotypic adhesion
(top; bar, 1 mm) and CD23 expression (treated
cells, black line; unstimulated cells, gray histo-
gram).
(B) Activation of human B cells by ChiLob 7/4 h1
and ChiLob 7/4 h2 whole IgG, F(ab0)2, or Fab0 for
16 hr at 1 mg/ml assessed by homotypic adhesion
(top; bar, 1 mm), CD23 upregulation (middle),
and proliferation (bottom). Means and ranges of
duplicate samples from one of four experiments.
(C) Proliferation of hCD40 Tg B cells WT or KO for
FcgRIIB with various concentrations of the indi-
cated ChiLob 7/4 isotypes determined by [3H]
thymidine incorporation (mean and range of
duplicates, one of four experiments).
(D) hCD40 Tg mice (n = 3–5) that were FcgR WT,
FcgRIIB KO, or common g chain KO (no activatory
FcgR) received OTI cells and then OVA plus the
indicated ChiLob 7/4 mAb. Circulating OTI cells
were enumerated at day 5. Combined results from
two experiments.
(E) hCD40Tg/FcgRIIB KOmice received OTI cells then were immunized with OVA alone (Con) or with 200 mg of ChiLob 7/4 h1 Fab02 or ChiLob 7/4 h2 Fab02 i.v. on
day 0 followed by 100 mg of Fab02 on days 1 and 2. Circulating OTI cells on day 5 are shown. Similar results were obtained when mice were given a single 100 mg
dose of h2 Fab02 i.v. (not shown). ***p < 0.001, *p < 0.05.
See also Figure S2.
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contrast, under the same conditions ChiLob 7/4 h1 was unable
to activate cells when added as IgG, F(ab0)2, or Fab0, although
when added in excess, each form prevented activation by
ChiLob 7/4 h2 (Figures 2B and S2F). Third, genetic deletion of
FcgRIIB from mouse B cells, the only FcgR expressed by these
cells, did not prevent their proliferation in response to ChiLob
7/4 h2 over a wide concentration range (Figure 2C), whereas
response to ChiLob 7/4 m1, that is dependent on FcgRIIB cross-
linking for activity (White et al., 2011), was lost (Figure 2C). Of
note, ChiLob 7/4 h2 produced a characteristic bell-shaped
response curve when used to stimulate B cells at different con-
centrations andwas active at very low levels in contrast to cross-
linking-dependent ChiLob 7/4 m1 whose activity increased as
concentrations rose (Figure 2D). These different curves presum-
ably reflect the different mechanisms by which the isotypes
impart agonistic activity and are discussed further below.
The FcgR-independent activity of ChiLob 7/4 h2 was also
confirmed in vivo. Genetic deletion of FcgRIIB, previously shown
to result in loss of agonistic activity of mAb against CD40 (Li and
Ravetch, 2011; White et al., 2011, 2014), Fas, DR4, and DR5 (Li
and Ravetch, 2012; Wilson et al., 2011; Xu et al., 2003) did not
reduce expansion of OVA-specific CD8 T cells induced by
ChiLob 7/4 h2 compared to that observed in wild-type (WT)
mice, whereas, as expected, activity of ChiLob 7/4 m1 was
lost in the FcgRIIB knockout (KO) (Figure 2D). Both mAbs re-
mained active in g chain KO mice that have no activatory FcgR
(Figure 2D). Finally, ChiLob 7/4 h2 provided robust stimulation
of CD8 T cell responses in vivo when administered as a F(ab0)2
fragment, whereas no response was observed with F(ab0)2 of
ChiLob 7/4 h1 (Figure 2E).CHuman IgG2 Is Agonistic for Multiple Targets
We next evaluated the influence of h2 constant regions on
the activity of another hCD40 mAb in clinical trial, SGN40, also
a chimeric h1 (Advani et al., 2009). The variable regions of
SGN40 were synthesized from the patent sequence and chimer-
ized onto h1 and h2 constant regions, to produce SGN40-Soton
h1 and SGN40-Soton h2. Similar to ChiLob 7/4, SGN40-Soton
h2 provided greater activation and proliferation of human B cells
than SGN40-Soton h1 (Figure 3A), and proliferation of hCD40 Tg
B cells in response to SGN40-Soton h2, but not its parental m1,
S2C6 (Hanks et al., 2005), was independent of FcgRIIB expres-
sion (Figure 3B). In addition, SGN40-Soton h2 significantly and
potently increased OVA-specific CD8 T cell responses in vivo
in FcgRIIB KO mice, whereas SGN40-Soton h1 did not (Fig-
ure 3C). Further studies with mAbs directed against two other
costimulatory receptors in clinical development, h4-1BB and
hCD28, revealed similar differences in h1 and h2 agonistic func-
tion assessed by human T cell proliferation in vitro (Figures 3D
and 3E). For hCD28, purified T cells were used. T cells generally
lack FcgR but displayed homotypic adhesion as well as
increased proliferation in response to anti-hCD28 h2, again sup-
porting an FcgR-independent mode of action (Figure 3E). Similar
to ChiLob 7/4 (Figure 1A), h4 constant regions did not confer
activity to anti-hCD28 in purified T cell cultures (Figure 3E).
Agonistic Activity Depends onBoth theHuman IgG2CH1
and Hinge Regions
As the variable regions of the h1 and h2 ChiLob 7/4 mAbs were
identical and the activity of h2 was independent of its Fc domain,
we examined the role of the CH1 and hinge domains of ChiLob 7/
4 h2 in agonistic activity. To this end we produced mutants inancer Cell 27, 138–148, January 12, 2015 ª2015 The Authors 141
Figure 3. Human IgG2 Is Agonistic for
Multiple Receptor Targets
(A)ActivationofhumanBcellswithSGN40-Sotonh1
or SGN40-Soton h2 was assessed as in Figure 1A
by homotypic adhesion (bar, 1 mm), CD23 upregu-
lation (black line, treated cells; gray histogram, un-
stimulated controls), and proliferation (duplicate
samples from one of five experiments shown).
(B) hCD40 Tg B cell proliferation (WT or FcgRIIB
KO) in response to SGN40 h1 and SGN40-Soton
h2 or the parental S2C6 m1 (mean and range of
duplicates, one of three experiments).
(C) hCD40Tg/FcgRIIB KOmice (n = 5) received OTI
cells and were then immunized with OVA alone
(Con) or with 100mg of SGN40-Soton h1 or SGN40-
Soton h2.CirculatingOTI cellswere enumerated on
D5. One of two experiments shown. ***p < 0.001.
(D) Proliferation of human CD4 T cells in total
PBMC cultures in response to chimeric h1, h2, or
h4 anti-h4-1BB.
(E) Activation assessed by homotypic adhesion
(bar, 1 mm) and proliferation of purified human
CD4 T cells in response to chimeric h1, h2, or h4
anti-hCD28. Points represent individual donors.
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domains of ChiLob 7/4 h1 and ChiLob 7/4 h2 were switched (Fig-
ure 4A). Domain swapping did not interfere with antigen binding
as assessed by flow cytometry (Figure S3). Comparative
agonistic activity of the different mAbs was assessed by their
ability to promote activation of human B cells and proliferation
of hCD40 Tg B cells in vitro (Figure 4A). When either the CH1
domain of h2 was replaced with that of h1 (CH1 1/2) or the
CH1 of h1 was replaced with that of h2 (CH1 2/1) (Figure 4A, i
and ii), little B cell proliferation was seen and human B cells
were not activated unless cells expressing high levels of FcgRIIB
were provided to crosslink the mAb. Thus, the presence of either
the h2 CH1 domain alone (in CH1 2/1) or the h2 hinge region
alone (in CH1 1/2) did not confer activity. Similarly, no activity
was seen when both the CH1 and hinge of h2 were replaced
with that of h1 (CH1Hge 1/2) (Figure 4A, iii). However, when the
CH1 and hinge of h1 were replaced with that of h2 (CH1Hge 2/
1) (Figure 4A, iv) robust human B cell activation and proliferation
of both FcgRIIB WT and KO hCD40 Tg B cells was observed,
similar to that seen with native h2. Similarly, in vivo, ChiLob 7/4
CH1Hge 2/1 produced significant increases in OVA-specific
CD8 T cell expansion, whereas ChiLob 7/4 CH1Hge 1/2 was
inactive (Figure 4B). These data show that the unusual agonistic
activity of h2 requires both its CH1 and hinge domains.
Human IgG2 Activity Is Dependent upon Its Disulfide
Bond Configuration
IgG2 is unique among human IgG in its ability to ‘‘shuffle’’ disul-
fide bonds in its CH1 and hinge regions (Figure 5), resulting in a
range of isoforms (Dillon et al., 2008; Martinez et al., 2008; Wy-
pych et al., 2008; Zhang et al., 2010). The molecule is believed
to be synthesized in its ‘‘h2A’’ form, wherein the heavy chain
(HC) Cys127 in CH1 is linked to Cys214 in the light chain (LC),
which then gradually converts in the blood through a series of
intermediates (Liu et al., 2008) to its ‘‘h2B’’ form in which HC
Cys127 and LC Cys214 form disulfide bonds with the HC hinge
Cys232 and Cys233 (Figure 5A). Importantly, physicochemical142 Cancer Cell 27, 138–148, January 12, 2015 ª2015 The Authorsproperties (Dillon et al., 2008) and electronmicroscopy (Ryazant-
sev et al., 2013) suggest that h2A has a classical IgG flexible ‘‘Y’’
conformation, whereas h2B adopts a more compact shape with
the Fab0 arms held in close proximity to the hinge. The h2A and
h2B forms can be distinguished by non-reducing capillary elec-
trophoresis (nrCE-SDS; Martinez et al., 2008) where they are
revealed as a double peak in unfractionated h2 compared to a
single peak for h1 (Figure 5B). Of the ChiLob 7/4 mAb mutants
analyzed above, only CH1Hge 2/1 retained a double peak on
nrCE-SDS (Figure 5B), supporting our hypothesis that disulfide
shuffling is important for agonistic activity.
To determine whether differentially disulfide-linked forms
of ChiLob 7/4 were associated with different agonistic activ-
ities, two approaches were taken. First, chemical ‘‘skewing’’ of
ChiLob 7/4 in redox buffer in the presence or absence of dena-
turant was used to enrich for h2A or h2B, respectively (Dillon
et al., 2008) (Figure 6A, top). This resulted in markedly different
activities, with much greater activation of hCD40 Tg B cells
with skewed h2B than h2A (Figure 6A). Similar differences in B
cell activation were observed when the skewed forms were
added to human B cells (Figure S4A), for skewed forms of the
ChiLob 7/4 CH1Hge 2/1 mutant (Figure S4B) and for the anti-
mouse CD40 mAb 3/23 where 3/23 h2B was able to activate
mouse B cells in soluble form, whereas h2A required coincuba-
tion with FcgRIIB-expressing crosslinking cells (Figure 6B; these
cells express non-physiologically high levels of FcgRIIB [White
et al., 2011] capable of crosslinking h2). The skewed h2B form
of ChiLob 7/4 was also able to activate FcgRIIB KO B cells as
bothwhole IgG (Figure 6C, i) or as aF(ab0)2 fragment (Figure S4C),
confirming its activity remained FcgR independent. Second,
mutagenesis was used to produce ‘‘locked’’ h2A- and h2B-like
forms as previously described (Allen et al., 2009; Martinez
et al., 2008). HC C232S or C233S mutation of ChiLob 7/4 pro-
duced homogenous h2A mAbs as assessed by nrCE-SDS (Fig-
ure 6D, HC C232S, HC C233S) that did not stimulate hCD40
Tg mouse B cell proliferation at any concentration tested over
a wide range (Figure 6C, ii and iii), whereas the h2B-like HC
Figure 4. The CH1 and Hinge Regions Confer Activity to ChiLob7/4 h2
(A) Schematics of ChiLob 7/4 h1 and ChiLob 7/4 h2 (left) and mutants (top) where the CH1 (i, CH1 1/2 and ii, CH1 2/1) or CH1 and hinge regions (iii, CH1Hge 1/2
and iv, CH1Hge 2/1) of h1 and h2were swapped.Middle: CD23 expression on humanB cells in the absence or presence of FcgRIIB-expressing crosslinking cells.
Bottom: hCD40 Tg FcgRIIB WT or KO B cell proliferation in response to the chimeric mAb (mean and range of duplicates).
(B) OTI responses in hCD40 Tg mice (n = 3) treated with the indicated mAb determined as in Figure 2E. Combined data from two experiments. ****p < 0.0001.
See also Figure S3.
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relative to native ChiLob 7/4 h2 at high concentrations for both
FcgRIIB WT and KO cells (Figure 6C, iv). These combined data
suggested that the FcgR-independent agonistic activity of h2
is contingent upon the precise conformation of disulfide bonds
in its hinge and CH1 domains, and specifically on its ability to
adopt the more compact h2B form.
Immune activation through CD40 ligation appears to require
receptor clustering in the cell membrane to allow tumor necrosis
factor receptor associated factor recruitment and propagation of
downstream intracellular signals. Many of the effects are medi-
ated through nuclear factor kB (NFkB) activation (Elgueta et al.,
2009). Experiments with both primary hCD40 Tg B cells (Fig-
ure 6E) and transformed human Ramos B cells (Figure S4D) re-
vealed a much greater capacity of ChiLob 7/4 h2B to activate
NFkB as reflected by greatly enhanced inhibitor of NFkB (IkB)
phosphorylation after cell stimulation compared to ChiLob 7/4
h2A. This is consistent with an ability of the more compact h2B
to promote clustering of CD40 in the membrane, leading to
NFkB signaling and cellular activation.
Mutagenesis Produces a Range of IgG2 Agonistic
Activities
Further studies revealed ChiLob 7/4 h2 could be manipulated to
achieve a range of agonistic activities. Mutation of LC Cys214
to Ser prevented the LC-HC disulfide linkage, resulting in two
peaks on nrCE-SDS (Figure 6D, LC C214S). However, the mAb
remained intact under nondenaturing conditions, with no reduc-
tion in binding to CD40 as measured by SPR (Figure 6F) or flow
cytometry (Figure S4E). LC C214S caused an increase in hCD40
Tg B cell proliferation similar to that of the C127S mutant (Fig-
ure 6C, i). However, LC C214S combined with HC 232S gave aCprofile similar to that of native h2 where activity was greatly
reduced at high concentrations (Figure 6C, ii), whereas LC
C214S combined with HC C233S provided maximum activity
similar to that of skewed h2B (Figure 6C, iii versus i).
As noted in the experiments described above, native ChiLob
7/4 h2 (a mixture of isoforms) produced a characteristic bell-
shaped concentration curve when used to stimulate B cells
in vitro, in which B cell responses were lower at high concentra-
tions (e.g., Figures 2D, 3B, and 6C, i). This effect was largely lost
with pure h2B, where high concentrations remained fully active
(Figure 6C), but it was recapitulated with a 1:1 mixture of h2A
and h2B (Figure 6G). Given the complete lack of response to
the h2A form, this suggests h2A can block the activity of h2B,
reducing its potency at high concentrations and suggesting
that h2A possesses a certain level of antagonistic activity.
Finally, differences in ChiLob 7/4 h2A and ChiLob 7/4 h2B ac-
tivity were recapitulated in vivo, where h2B caused significantly
greater expansion of both OVA-specific CD8 T cells (Figure 6H)
and OVA-specific IgG (Figure 6I) than h2A in hCD40 Tg FcgRIIB
KO mice. Similar differences in in vivo activity were observed for
h2A and h2B skewed forms of the CH1Hge 2/1 mutant (Figures
S4F and S4G). In conclusion, our data demonstrate that manip-
ulation of the disulfide structure of h2 may enable the production
of therapeutic agents with defined and diverse immunostimula-
tory function that, importantly, is independent of the presence
of FcgR in target tissues.
DISCUSSION
The recent clinical success of Ab immunotherapy has intensified
the search for more effective immunostimulatory mAb in cancer
treatment (Brahmer et al., 2012; Hodi et al., 2010; Topalian et al.,ancer Cell 27, 138–148, January 12, 2015 ª2015 The Authors 143
A B Figure 5. Disulfide Shuffling in the Human
IgG2 Hinge
(A) Schematic representation of differently disul-
fide-linked h2 isoforms as described, for example,
by Martinez et al. (2008).
(B) nrCE-SDS profiles of the indicated ChiLob 7/4
mAb. Positions of h2A and h2B and a 10 kDa
standard are indicated.
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that isotype selection is crucial as it dictates differential FcgR in-
teractions that direct events after antigen binding (Nimmerjahn
and Ravetch, 2012; White et al., 2013). Manipulation of the
mAb Fc has already been used as a way to enhance selected
interactions and increase therapeutic potency (Li and Ravetch,
2012, 2013; White et al., 2013). The data in this report show
that isotype-dependent, FcgR-independent mechanisms may
also be important determinants of activity.
The finding by us and others that agonistic anti-CD40, at least
in murine models, requires binding to FcgRIIB (Li and Ravetch,
2011; White et al., 2011) poses a challenge when developing
agents for human use as human IgG bind to FcgRIIB with very
low affinity, particularly as monomers (Bruhns et al., 2009).
Although Fc engineering can enhance FcgRIIB interaction and
improve activity (Li and Ravetch, 2012, 2013; White et al.,
2013), this approach is limited by the fact that FcgRIIB may not
always be available for crosslinking within the tumor microenvi-
ronment and may also result in adverse events when FcgRIIB
is engaged on endothelial cells (Xu et al., 2003). The demonstra-
tion in this report that mAb of the h2 isotype possess FcgR-inde-
pendent agonistic activity is thus significant as it provides the
opportunity to develop reagents that are agonistic regardless
of target cell location.
The human IgG2 isotype is unique in its ability to rearrange
disulfide bonds within its hinge and CH1 domains after synthe-
sis, resulting in a range of isoforms with distinct conformations
(Allen et al., 2009; Dillon et al., 2008; Martinez et al., 2008; Wy-
pych et al., 2008). It is believed to be synthesized with a classical,
flexible IgG structure (its ‘‘A’’ form) containing four inter-HC hinge
disulfide bonds. Over time this is converted through a series of
intermediates to a more compact ‘‘B’’ form in which the LC
and HC CH1 are disulfide bonded to HC hinge cysteines 232
and 233 (Allen et al., 2009; Dillon et al., 2008; Liu et al., 2008;
Martinez et al., 2008;Wypych et al., 2008). Using both a chemical
skewing approach and a series of genetically engineered mAbs,144 Cancer Cell 27, 138–148, January 12, 2015 ª2015 The Authorswe have demonstrated that the agonistic
activity of ChiLob 7/4 h2 is dependent
upon its ability to adopt the h2B form.
Moreover, mutation of specific cysteines
or combinations thereof could lock it
into conformations with different degrees
of agonistic activity.
Of note, the selected LC appears to
affect the ability of h2 to adopt different
conformations, with disulfide shuffling
permitted by kappa but not lambda LCs
(Dillon et al., 2008). Consistent with this,
all mAbs used in our study containedthe kappa LC. Of further interest, the existence of disulfide linked
h2 dimers has been described in human blood (Yoo et al., 2003).
However, as also reported by others using recombinant mAbs
(Martinez et al., 2008), we found no evidence of dimers in any
of our mAb preparations, as revealed by nrCE-SDS.
Previous attempts to investigate the functional impact of h2A
and h2B isoforms have not revealed differences in FcgR or
C1q engagement (Lightle et al., 2010), or consistent differences
in Ag binding or the ability to block receptor-ligand interactions,
where if anything h2B is less active (Dillon et al., 2008; Guo et al.,
2008;Martinez et al., 2008). Similarly, we did not observe any dif-
ference in the avidity of ChiLob 7/4 h2A and h2B forms for CD40
when measured by SPR or by flow cytometry. Combined with
the very similar affinities of ChiLob 7/4 h1 and ChiLob 7/4 h2
Fab0 for CD40, it seems highly unlikely that changes in affinity
can explain the very different properties of h2A and h2B. Inter-
estingly, Liu et al. (2008) also showed in patients the natural con-
version from the A-to-B form over a number of days that did not
result from a change in half-life. In the current study we assessed
the agonistic activity of mAbs engaging immune coreceptors,
where we know that receptor clustering is a mandatory require-
ment to initiate downstream immune activation (Elgueta et al.,
2009). Finding an Ab format that can achieve such crosslinking
without FcgR engagement is both unexpected and unexplained,
as almost all agonistic mAbs described to date, including the
anti-CD28 superagonist TGN1412, which caused catastrophic
toxicity in healthy volunteers in 2006 (Suntharalingam et al.,
2006), require FcgR crosslinking for activity (Bartholomaeus
et al., 2014). We speculate that the agonistic properties of h2B
result from its unusual compact conformation where the Fab0
arms are rotated down close to the Fc region of the Ab. This
may allow close ‘‘packing’’ of adjacent receptors engaged in
the plane of the membrane. The lack of flexibility in h2B may
also hold receptors in a more rigid lattice that favors efficient
downstream signaling. An extension of this may be that h2B, un-
like h2A, can stabilize receptors in preexisting clusters (Smulski
Figure 6. Mutagenesis Generates a Range of ChiLob 7/4 h2 Agonistic Forms
(A) nrCE-SDS profiles (top) and hCD40 Tg B cell proliferation in response to ‘‘skewed’’ h2A and h2B ChiLob 7/4 (mean and range of duplicates, one of three
experiments).
(B) nrCE-SDS profiles (top) and mouse B cell activation assessed by CD23 upregulation in the presence and absence of FcgRIIB-expressing crosslinking cells
(bottom) in response to skewed 3/23 h2 (one of three experiments shown).
(C) Proliferation of hCD40 Tg B cells that were WT or KO for FcgRIIB in response to ChiLob 7/4 mutants (mean and range of duplicates from one of at least three
experiments).
(D) nrCE-SDS profiles of the indicated ChiLob 7/4 mutants. Positions of whole IgG, HC-HC complexes (HH), free LC (L), and 10 kDa marker are shown.
(E) Western blot of lysates from hCD40 Tg mouse B cells treated with ChiLob 7/4 h2A and ChiLob 7/4 h2B at 1 mg/ml for the indicated times and probed with Ab
specific for phospho (p)-IkB kinase (IKK) a/b, pIkB-a, or IkB-a. Anti-tubulin was used as a loading control.
(F) SPR of ChiLob 7/4 h2 mutants (100, 20, 4, 0.8, and 0.16 nM) binding to hCD40 immobilized at 8,000 response units (RU).
(G) hCD40 Tg B cell proliferation with ChiLob 7/4 h2, h2A (HC C233S), skewed h2B, or a 1:1 mixture of h2A:h2B. Mean and range of duplicates from one of more
than five experiments.
(H and I) OVA-specific OTI CD8 T cell responses (H) and day 18 serum Ab responses (I) in hCD40 Tg FcgRIIB KOmice (n = 5) immunized with OVA plus 100 mg of
ChiLob 7/4 C233S (h2A) or skewed h2B. Results from one of two experiments. **p < 0.01, ***p < 0.001.
See also Figure S4.
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these clusters. As h2 is the predominant isotype produced in
response to bacterial polysaccharides (Barrett and Ayoub,
1986), the ability to form h2B may be an evolutionary response
driven by the need to engage these repetitive, closely packed
epitopes. The ability of h2B to engage such closely packed epi-
topes is the subject of our ongoing research.
The characteristic bell-shaped curves observed in this study
whenmixtures of anti-CD40 h2A and h2Bwere used to stimulate
B cells whereby decreased activity was seen at higher concen-
trations (e.g., Figure 2D) may reflect the ability of the more
flexible h2A form to outcompete crosslinking by the more struc-Cturally constrained h2B form. This could perhaps be due to the
flexible h2A binding more efficiently to target molecules that
are continually moving in a fluid plasma membrane. Ongoing
studies aim to determine the precise configurations of the
different forms of h2 to shed light on their precise modes of
action. The observation that h2 constant regions also conferred
FcgR-independent activity on another anti-hCD40mAb, SGN40,
as well as mAb directed against other receptors (4-1BB and
CD28) suggests this may be a general property of this restricted
conformation.
In vivo experiments in hCD40Tg mice clearly demonstrated
the different mechanisms of action of ChiLob 7/4 whenancer Cell 27, 138–148, January 12, 2015 ª2015 The Authors 145
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immunostimulation was observed; however, the activity of m1
was dependent upon FcgRIIB expression, whereas that of h2
was completely independent of FcgR interaction. This raises
the possibility of further enhancing activity by engineering re-
agents to simultaneously engage both mechanistic pathways;
for example, a chimeric CH1Hge 2/1 containing the S267E/
L328F mutation to increase FcgRIIB affinity (Chu et al., 2008).
This is the subject of ongoing investigation. In addition, although
h2 activity in our study was FcgR independent, it will be impor-
tant to determine whether its activity can be influenced in vivo
by the presence of human FcgR that may bind h2 immobilized
on the cell surface with sufficient affinity to allow crosslinking,
particularly in patients expressing FcgRIIA-131H or FcgRIIIA-
158V (Lux et al., 2013).
Importantly, the most agonistic of the anti-CD40 mAbs in
clinical trial to date is CP870,893, which is an h2, unlike the
less agonistic ChiLob 7/4 and SGN40, which are both h1. The
maximum tolerated dose of CP870,893 is at least 10-fold lower
than that for ChiLob 7/4 or SGN40 (Vonderheide and Glennie
2013), and promising clinical data are emerging with this agent
in both pancreatic cancer and metastatic melanoma patients
(Bajor et al., 2014; Beatty et al., 2013). As in the current study,
Richman and Vonderheide (2014) recently demonstrated that
the in vitro agonistic activity of CP870,893 is both Fc indepen-
dent and FcgR independent. This is significant as it suggests
that FcgR-independent pathways can deliver results in a clinical
setting, and our current findings might go some way toward
explaining the unusual potency of CP870,893.
The data presented have profound implication for the devel-
opment of agonistic mAb-based therapeutics. Equipped with
these insights, it should be possible to manipulate the disulfide
bond configuration of h2 to control the activity and toxicity of
mAbs directed against a range of immune receptors, thereby
permitting the fine-tuning of biological function and the subse-
quent development of novel therapeutics independent of FcgR
interaction.
EXPERIMENTAL PROCEDURES
Mice
C57Bl/6 and RAG/mice were from Charles River Laboratories. Other genet-
ically altered strains (all on C57BL/6 background) were FcgRIIB/ (Boross
et al., 2011), OTI TCR Tg (kindly provided by Dr. Matthias Merkenschlager, Im-
perial College), and human CD40 Tg (hCD40 Tg) (kindly provided by Randolph
Noelle, Kings College) (Ahonen et al., 2002). Human CD40 Tg/FcgRIIB/ and
g chain/ mice were generated by crossbreeding with genotypes confirmed
by flow cytometry. Animals were bred and housed in a local animal facility and
were used at approximately 8–12weeks of age. All experiments were reviewed
and approved by both the Science Review Group and the Animal Welfare and
Ethical Review Board, University of Southampton, and were carried out under
UK Home Office license numbers PPL30/2451 and PPL30/2964.
Antibodies and Reagents
The following hybridomas were used: anti-human CD23 (MHM6) was from J.
Gordon (University of Birmingham). Anti-human FcgRII (AT10) that binds
both FcgRIIA and -IIB (Greenman et al., 1991), anti-human FcgRIIB (KB61),
anti-human CD40 (ChiLob 7/4; Chowdhury et al., 2014), and anti-human
4-1BB were produced in house using conventional hybridoma technology.
Anti-mouse CD23-phycoerythrin (PE) was from BD Biosciences. For OTI cell
staining, APC-anti-mouse CD8a (clone 53-6.7; BD Biosciences) and PE-
labeled SIINFEKL tetramers produced in house as described previously (White146 Cancer Cell 27, 138–148, January 12, 2015 ª2015 The Authorset al., 2011) were used. Flow cytometry was performed using an FACSCalibur
system (BD Biosciences). Chicken OVA was from Sigma-Aldrich. Endotoxin-
free OVA was from Profos.
Chimeric Antibodies
DNA constructs encoding HC and LC (kappa) variable regions of various mAbs
were either amplified from hybridoma by PCR reactions or synthesized by
Genewiz. The anti-CD40 mAb SGN40-Soton and the anti-CD28 TGN-Soton
were produced using published sequences (Drachman et al., 2007 and Hanke
et al., 2009, respectively). Details of mAb purification and quality control
methods can be found in Supplemental Experimental Procedures.
Immunization and Assessment of Immune Responses
Mice were immunized as detailed for individual experiments via tail vein injec-
tion in 200 ml of PBS. Serum anti-OVA Ab levels were determined by ELISA
(White et al., 2010). In some experiments, 3 3 105 splenic OVA-specific CD8
(OTI) T cells were given via tail vein the day before immunization.
Tumor Therapy
For vaccination against the OVA-expressing thymoma EG7, mice were adop-
tively transferred with 53 104 OTI cells on day6 and then received 0.5 mg of
Sigma OVA + 100 mg of anti-CD40 mAb on day 5. The mice were challenged
with 5 3 105 EG7 tumor cells subcutaneously on day 0. Tumor growth was
monitored, and mice were sacrificed when the humane endpoint was reached
(15 mm mean tumor diameter when taking the two greatest perpendicular
measurements). B cell lymphoma (BCL1) therapies were performed as
described previously (White et al., 2014). In brief, mice were inoculated via
tail vein with 1 3 104 BCL1 cells on day 0. On day 14 (when the tumor was
well established and represented 5%–10% spleen weight), mice were treated
with a single 100 mg dose of anti-CD40.
Cell Activation and Proliferation
Details of the isolation and assays to assess the activation and/or proliferation
of DCs, B cells, and T cells can be found in Supplemental Experimental Proce-
dures. For isolation of human Langerhans cells, skin specimens were acquired
from healthy individuals. For peripheral blood B cells, anonymized leukocyte
reduction system cones from healthy adult subjects were obtained from the
National Blood Transfusion Service, Southampton, UK. All human samples
were collected following informed consent and used under ethical approval
(National Research Ethics Service, UK) in accordance with the Declaration
of Helsinki.
SPR
A Biacore T100 system (GE Healthcare) was used to assay the interaction
between soluble Fcg receptors and ChiLob 7/4 mAb isotypes, as well as be-
tween soluble mAb and immobilized CD40, as described in Supplemental
Experimental Procedures.
Statistical Analyses
Student’s t tests (unpaired, two-tailed) and survival analyses (log rank Mantel-
Cox tests) were performed using Prism software (GraphPad). For comparison
of Ab responses, data were log transformed before analysis. In some cases
data frommultiple experiments were combined. However, this was not always
possible as although relative differences remained the same between experi-
ments, absolute measures often varied too much to allow combination. When
this was the case, a single representative experiment is shown, with the num-
ber of experiments performed stated in the figure legend.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at http://dx.doi.org/
10.1016/j.ccell.2014.11.001.
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